Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

BioStock: Progress for Stayble Therapeutics in the second quarter

Stayble Therapeutics

The second quarter was an intense period with several important achievements for the Gothenburg-based pharmaceutical company Stayble Therapeutics. After a successful capital raise, the company can run the two ongoing studies with STA363 at the desired pace. According to the plan, the phase IIb study in degenerative disc disease will be completed in the second half of 2023. The company also looks forward to treating the first patient in the phase Ib study in herniated discs.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/08/progress-for-stayble-therapeutics-in-the-second-quarter/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.